


## **Supplemental Figures**

**Lung function associated gene Integrator Complex subunit 12  
regulates protein synthesis pathways**



Kheirallah et al.

**Figure S1: Qualitative comparison of biological replicates of INTS12 protein knockdown.**


Representative images from the first experiment are shown in the first column and are compared to the images from the independent experiment shown in the second column. Based on these observations it is possible to say that D-siRNA treatment resulted in INTS12 protein depletion and indicates the specificity of used antibody as there is a notable decrease of staining among cells in which RNAi was initiated. In agreement with previous reports, INTS12 appears to have a nuclear sub-cellular localization.



D-siRNA INTS12  
knockdown




Isotype control




**Figure S2: qPCR expression profiling of LEP expression in additional donor cells.**

LEP is significantly upregulated in validation donor HBECs depleted of INTS12. Statistical tests were performed comparing to scrambled D-siRNA control: \* $P < 0.05$ , \*\*\*\* $P < 0.0001$ . Individual  $\Delta\Delta C_t$  gene expressions are *GAPDH* normalized and relative to the mean of the scrambled D-siRNA condition. No significant difference was observed between un-transfected and scrambled D-siRNA transfected cells.



**Figure S3: Box plots representing  $\log_{10}$  of RNAseq FPKM expression values of genes belonging to the top dysregulated pathways.**


Stars indicate the GSEA-derived significance of pathway dysregulation.



**Figure S4: Enrichment plots of pathways upregulated by INTS12 knockdown.**

Enrichment plots of reproducibly upregulated pathways in D-siRNA A and C analyses are shown with indicated statistical significance and normalized enrichment scores of their respective upregulations. The FDR and normalized enrichment score values were rounded up to one and three significant figures respectively.


**D-siRNA A analysis**



FDR = 0.01


Normalized enrichment score = 1.87

**D-siRNA C analysis**




FDR < 0.00001

Normalized enrichment score = 2.42




FDR = 0.03

Normalized enrichment score = 1.78




FDR < 0.00001

Normalized enrichment score = 2.40



FDR = 0.04

Normalized enrichment score = 1.74




FDR = 0.05

Normalized enrichment score = 1.64




## Aldosterone regulated sodium re-absorption (KEGG)



**Figure S6: Enrichment plots of pathways downregulated by INTS12 knockdown.**

Enrichment plots of reproducibly downregulated pathways in D-siRNA A and C analyses, except cytosolic tRNA aminoacylation (REACTOME) and PERK regulated gene expression (REACTOME), are shown with indicated statistical significance and normalized enrichment score of their respective downregulations. The FDR and normalized enrichment score values were rounded up to one and three significant figures respectively.


**D-siRNA A analysis**



FDR = 0.0004


Normalized enrichment score = -2.05

**D-siRNA C analysis**




FDR = 0.00009

Normalized enrichment score = -2.10




FDR = 0.002

Normalized enrichment score = -1.95




FDR = 0.00006

Normalized enrichment score = -2.12




FDR = 0.003

Normalized enrichment score = -1.90




FDR = 0.004

Normalized enrichment score = -1.92




FDR = 0.004

Normalized enrichment score = -1.89




FDR = 0.003

Normalized enrichment score = -1.94




FDR = 0.003

Normalized enrichment score = -1.91




FDR = 0.03

Normalized enrichment score = -1.72




FDR = 0.006

Normalized enrichment score = -1.86




FDR = 0.0001

Normalized enrichment score = -2.10




FDR = 0.03

Normalized enrichment score = -1.72




FDR = 0.02

Normalized enrichment score = -1.79



FDR = 0.01

Normalized enrichment score = -1.80




FDR = 0.03

Normalized enrichment score = -1.74


**Figure S7 Gene expression heatmaps of genes belonging to reproducibly downregulated pathways.**

Green and red colours on the Z-scale indicate lower and higher expression respectively. Samples were clustered by unsupervised hierarchical clustering and resulted in clustering of three biological replicate samples of each of the four conditions: un-transfected cells (UT), cells transfected with scrambled D-siRNA control (NC), cells transfected with anti-*INTS12* D-siRNA A (A) and cells transfected with anti-*INTS12* D-siRNA C (C).

**Unfolded protein response (REACTOME)**



**Activation of genes by ATF4 (REACTOME)**









**Figure S8: Biological reproducibility of INTS12 knockdown.**

Correlation of ChIPseq signals in donor replicates of active regions defined by the start coordinate of the most upstream interval and the end coordinate of the most downstream interval (a union of donor 1 and donor 2 intervals) revealed a Pearson's correlation of 0.85 ( $P < 0.0001$ ).




**Figure S9: ChIP-PCR validation of ChIPseq findings.**

Three ChIPseq positive binding sites (*POR*, *ACTB*, *NBPF1*) shown in green boxes and one negative binding site (*Untr12*) shown in blue box were selected for ChIP-PCR testing to determine the number of binding events detected per thousand donor 1 (D1) and donor 2 (D2) cells. ChIP-PCR results corresponded well with ChIPseq data as seen on the genome browser.



**Figure S10: INTS12 ChIPseq peaks over the human genome in donor 1 and donor 2 cells.**




**Figure S11: The distance between the average of distribution of intersection in random shuffling of target sites and the observed number of overlaps with INTS12 binding.**

Random walk represents the frequency distribution of overlaps between INTS12 and test regions generated by shuffling H3K4me3, H3K36me3, H3K27me3, DNaseI and CTCF sites in thousand times permutation test. The larger the Z-score distance between the observed and permuted distribution of intersection, the less likely it is to have occurred by chance. Negative Z-score indicates that the observed connection is less than expected by chance.

### INTS12 vs H3K4me3

Z-score: 347.554  
n perm: 1000  
randomization: circularRandomizeRegions




### INTS12 vs H3K36me3

Z-score: 13.045

n perm: 1000

randomization: circularRandomizeRegions




### INTS12 vs H3K27me3

Z-score: -11.486


n perm: 1000

randomization: circularRandomizeRegions




### INTS12 vs DNaseI

Z-score: 223.163  
n perm: 1000  
randomization: circularRandomizeRegions




### INTS12 vs CTCF

Z-score: 263.924  
n perm: 1000  
randomization: circularRandomizeRegions



**Figure S12: Correlation of INTScom members at 48h and 120h. Numbers and colours are indicative of Pearson's correlation coefficients. INTS12 column is highlighted in red box next to the average of coefficients.**

INTS12 appears to have poor correlation with other INTScom members in HBECS suggesting its functional independence from the rest of the complex.





## **Supplemental Tables**

**Lung function associated gene Integrator Complex subunit 12 regulates protein synthesis pathways**

Kheirallah et al.

**Table S1: Hits of the INTS12 BLASTP search against a database of human proteins.**

BLASTP search identified significant sequence similarity between canonical full length human INTS12 protein (NP\_001135943.1) and PHD finger family.

<b>BLASTP SEARCH HITS</b>						
<b>Description</b>	<b>Max score</b>	<b>Total score</b>	<b>Query cover</b>	<b>E value</b>	<b>Ident</b>	<b>Accession</b>
PHD finger protein 1 isoform b	50.8	50.8	11%	3.00E-06	39%	NP_077084.1
PHD finger protein 1 isoform a	50.4	50.4	11%	4.00E-06	39%	NP_002627.1
PHD finger protein 21A isoform a	45.4	45.4	11%	2.00E-04	40%	NP_001095272.1
PHD finger protein 21A isoform b	44.7	44.7	14%	3.00E-04	37%	NP_057705.3
sp110 nuclear body protein isoform a	42.7	42.7	12%	0.001	40%	NP_004500.3
histone-lysine N-methyltransferase 2A isoform 1 precursor	43.1	43.1	11%	0.001	38%	NP_001184033.1
histone-lysine N-methyltransferase 2A isoform 2 precursor	43.1	43.1	11%	0.001	38%	NP_005924.2
sp110 nuclear body protein isoform c	42.7	42.7	12%	0.001	40%	NP_536349.2
metal-response element-binding transcription factor 2	41.6	41.6	11%	0.002	30%	NP_031384.1

isoform a						
metal-response element-binding transcription factor 2 isoform c	40.8	40.8	11%	0.004	30%	NP_001157863.1
metal-response element-binding transcription factor 2 isoform b	40.8	40.8	11%	0.005	30%	NP_001157864.1
bromodomain adjacent to zinc finger domain protein 2B isoform a	38.1	38.1	27%	0.034	25%	NP_038478.2
bromodomain adjacent to zinc finger domain protein 2B isoform b	38.1	38.1	27%	0.038	25%	NP_001276904.1

**Table S2: Summary of proteins with sequence similarity to INTS12.**

Summary of proteins showing sequence similarity to human INTS12 provide evidence for putative chromatin and gene regulation roles.

<b>INTS12-SIMILAR PROTEIN SUMMARIES</b>	
PHD finger protein 1 isoform a and b	This gene encodes a Polycomb group protein. The protein is a component of a histone H3 lysine-27 (H3K27)-specific methyltransferase complex, and functions in transcriptional repression of homeotic genes. The protein is also recruited to double-strand breaks, and reduced protein levels results in X-ray sensitivity and increased homologous recombination. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2009]
PHD finger protein 21A isoform a and b	The PHF21A gene encodes BHC80, a component of a BRAF35 (MIM 605535)/histone deacetylase (HDAC; see MIM 601241) complex (BHC) that mediates repression of neuron-specific genes through the cis-regulatory element known as repressor element-1 (RE1) or neural restrictive silencer (NRS) (Hakimi et al., 2002 [PubMed 12032298]).[supplied by OMIM, Nov 2010].
sp110 nuclear body protein isoform a and c	The nuclear body is a multiprotein complex that may have a role in the regulation of gene transcription. This gene is a member of the SP100/SP140 family of nuclear body proteins and encodes a leukocyte-specific nuclear body component. The protein can function as an activator of gene transcription and may serve as a nuclear hormone receptor coactivator. In addition, it has been suggested that the protein may play a role in ribosome biogenesis and in the induction of myeloid cell differentiation. Alternative splicing has been observed for this gene and three transcript variants, encoding distinct isoforms, have been identified. [provided by RefSeq, Jul 2008]
histone-lysine N-methyltransferase 2A isoform 1 and 2 precursor	This gene encodes a transcriptional coactivator that plays an essential role in regulating gene expression during early development and hematopoiesis. The encoded protein contains multiple conserved functional domains. One of these domains, the SET domain, is responsible for its histone H3 lysine 4 (H3K4) methyltransferase activity which mediates chromatin modifications associated with epigenetic transcriptional activation. This protein is processed by the enzyme Taspase 1 into two fragments, MLL-C and MLL-N. These fragments reassociate and further assemble into different multiprotein complexes that regulate the transcription of specific target genes, including many of the HOX genes. Multiple chromosomal translocations involving this gene are the cause of certain acute lymphoid leukemias and acute myeloid leukemias. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Oct 2010]

metal-response element-binding transcription factor 2 isoform a, b and c	No description available
bromodomain adjacent to zinc finger domain protein 2B isoform a	No description available

**Table S3: Sequences of D-siRNAs used for INTS12 knockdown.**

<b>Oligo</b>	<b>Sequence</b>
D-siRNA #A	5'-GGAAUGGAAAUAGUGGAACAUCAGG-3'
D-siRNA #B	5'-GGCAAUCAAUUAGUAGAAUGUCAGG-3'
D-siRNA #C	5'-GCGUUUAAGAGAACAGAAGUCAAGA-3'

**Table S4: Sequences of forward and reverse primers/probes used in snRNA processing and gene expression qPCR assays.**

<b>SYBR Green</b>		
<b>Target</b>	<b>Oligo</b>	<b>Sequence</b>
Immature U1	Forward primer	5'-GATGTGCTGACCCCTGCGATTTTC-3'
	Reverse primer	5'-GTCTGTTTTTGAAGCTCCAGAAAAGTC-3'
Immature U2	Forward primer	5'-TTGCAGTACCTCCAGGAACGG-3'
	Reverse primer	5'-CAGGGAAGCAGTTAAGTCAAGCC-3'
Immature U4	Forward primer	5'-AGCTTTGCGCAGTGGCAGTATCG-3'
	Reverse primer	5'-AGCTTTGCGCAGTGGCAGTATCG-3'
Immature U5	Forward primer	5'-TACTCTGGTTTCTCTTCAGATCGC-3'
	Reverse primer	5'-TTCTATTGTTGGATTACCAC-3'
MARS	Forward primer	5'-TACCCATTACTGCAAGATCC-3'
	Reverse primer	5'-CTTGCTGTTTCAGTACAGTC-3'
GARS	Forward primer	5'-GTGTTAGTGGTCTGTATGAC-3'
	Reverse primer	5'-GTCTTTAAAGCTGGCTCAGG-3'
ASNS	Forward primer	5'-GATTGGCTGCCTTTTATCAG-3'
	Reverse primer	5'-AATTGCAAATGTCTGGAGAG-3'
ATF4	Forward primer	5'-CCTAGGTCTCTTAGATGATTACC-3'
	Reverse primer	5'-CAAGTCGAACTCCTTCAAATC-3'
LEP	Forward primer	5'-TCAATGACATTTACACACAG-3'
	Reverse primer	5'-TCCATCTTGGATAAGGTCAG-3'
<b>TaqMan</b>		
INTS12	Forward primer	5'-CTCCAGCTGTCAAAGATCCATT-3'
	Reverse primer	5'-GAGAGCTGCTGGATTCTGAAGT-3'
	Probe	5'-TGGCTGCAAAGCTGCCCATCCAG-3'

**Table S5: Sequences of forward and reverse primers used in ChIP-PCR assays of INTS12 binding to the indicated sites.**

<b>Target gene/primer</b>	<b>Primer sequence</b>	<b>Site (hg19)</b>	<b>Type of binding</b>
<i>POR</i> forward	5'-CAGGGTCCGAGCTGTAGAAG-3'	TSS-145	Positive
<i>POR</i> reverse	5'-CCGGCAGAGAAATGAAAGTG-3'		
<i>NBPF1</i> forward	5'-CACCTACGCCTCCCAGTACC-3'	TSS+108	Positive
<i>NBPF1</i> reverse	5'-GCCTTGGGTTATCCTGACAC-3'		
<i>ACTB</i> forward	5'-AACTCTCCCTCCTCTTCC-3'	TSS-154	Positive
<i>ACTB</i> reverse	5'-CCTCTCCCCTCCTTTTGC-3'		
<i>Untr12</i> forward	5'-TGAGCATTCCAGTGATTTATTG-3'	Chr12:61667747-61667824	Negative
<i>Untr12</i> reverse	5'-AAGCAGGTAAAGTCCATATTTTC-3'		

**Table S6: A summary of the survey of scientific literature that investigated the effect of INTScom members on snRNA processing. Ezzedine et al. 2011, Chen et al. 2012 and Chen et al. 2013 studies were undertaken on fly S2 cells while Baillat et al. 2005 study was undertaken on human HeLa cells.**

<b>Study</b>	<b>INTScom protein targeted</b>	<b>Effect on snRNA processing</b>
Ezzedine et al. 2011	INTS1	Moderate
Ezzedine et al. 2011	INTS2	Strong
Ezzedine et al. 2011	INTS3	Very weak
Ezzedine et al. 2011	INTS4	Very strong
Ezzedine et al. 2011	INTS5	Moderate
Ezzedine et al. 2011	INTS6	Weak
Ezzedine et al. 2011	INTS7	Weak
Ezzedine et al. 2011	INTS8	Moderate
Ezzedine et al. 2011	INTS9	Very strong (two experiments)
Ezzedine et al. 2011	INTS10	Very weak
Ezzedine et al. 2011	INTS11	Strong
Ezzedine et al. 2011	INTS12	Very weak (one experiment) and weak (another experiment)
Ezzedine et al. 2011	INTS1	Moderate
Ezzedine et al. 2011	INTS2	Strong
Ezzedine et al. 2011	INTS3	Very weak
Ezzedine et al. 2011	INTS4	Very strong
Ezzedine et al. 2011	INTS5	Moderate
Ezzedine et al. 2011	INTS6	Weak
Ezzedine et al. 2011	INTS7	Weak
Ezzedine et al. 2011	INTS8	Moderate
Ezzedine et al. 2011	INTS9	Very strong (two experiments)
Ezzedine et al. 2011	INTS10	Very weak
Ezzedine et al. 2011	INTS11	Strong
Ezzedine et al. 2011	INTS12	Very weak (one experiment) and weak (another experiment)
Ezzedine et al. 2011	INTS1	Above 30 and below 100 fold relative to control

Ezzedine et al. 2011	INTS2	Below 3 fold relative to control
Ezzedine et al. 2011	INTS3	Less than 1 fold relative to control
Ezzedine et al. 2011	INTS4	300 fold relative to control
Ezzedine et al. 2011	INTS5	Below 3 fold relative to control
Ezzedine et al. 2011	INTS6	Below 3 fold relative to control
Ezzedine et al. 2011	INTS7	10 fold relative to control
Ezzedine et al. 2011	INTS8	Below 3 fold relative to control
Ezzedine et al. 2011	INTS9	Above 100 but below 300 fold relative to control
Ezzedine et al. 2011	INTS10	Below 3 fold relative to control
Ezzedine et al. 2011	INTS11	Above 3 but below 10 fold relative to control
Ezzedine et al. 2011	INTS12	Below 3 fold relative to control
Ezzedine et al. 2011	INTS1	Above 30 and below 100 fold relative to control
Ezzedine et al. 2011	INTS2	Above 3 but below 10 fold relative to control
Ezzedine et al. 2011	INTS3	Less than 1 fold relative to control
Ezzedine et al. 2011	INTS4	Above 300 and below 1000 fold relative to control
Ezzedine et al. 2011	INTS5	Above 10 fold relative to control
Ezzedine et al. 2011	INTS6	Above 3 but below 10 fold relative to control
Ezzedine et al. 2011	INTS7	10 fold relative to control
Ezzedine et al. 2011	INTS8	Above 3 but below 10 fold relative to control
Ezzedine et al. 2011	INTS9	Above 100 but below 300 fold relative to control
Ezzedine et al. 2011	INTS10	Below 3 fold relative to control
Ezzedine et al. 2011	INTS11	Above 10 but below 30 fold relative to control
Ezzedine et al. 2011	INTS12	Above 3 but below 10 fold relative to control
Ezzedine et al. 2011	INTS1	30 fold relative to control

Ezzedine et al. 2011	INTS2	Below 3 fold relative to control
Ezzedine et al. 2011	INTS3	Less than 1 fold relative to control
Ezzedine et al. 2011	INTS4	Above 30 and below 100 fold relative to control
Ezzedine et al. 2011	INTS5	3 fold relative to control
Ezzedine et al. 2011	INTS6	Below 3 fold relative to control
Ezzedine et al. 2011	INTS7	10 fold relative to control
Ezzedine et al. 2011	INTS8	Below 3 fold relative to control
Ezzedine et al. 2011	INTS9	30 fold relative to control
Ezzedine et al. 2011	INTS10	Below 3 fold relative to control
Ezzedine et al. 2011	INTS11	3 fold relative to control
Ezzedine et al. 2011	INTS12	Below 3 fold relative to control
Ezzedine et al. 2011	INTS1	Above 30 and below 100 fold relative to control
Ezzedine et al. 2011	INTS2	Above 3 but below 10 fold relative to control
Ezzedine et al. 2011	INTS3	Below 3 fold relative to control
Ezzedine et al. 2011	INTS4	300 fold relative to control
Ezzedine et al. 2011	INTS5	Above 10 fold relative to control
Ezzedine et al. 2011	INTS6	Above 3 but below 10 fold relative to control
Ezzedine et al. 2011	INTS7	Above 10 but below 30 fold relative to control
Ezzedine et al. 2011	INTS8	Above 3 but below 10 fold relative to control
Ezzedine et al. 2011	INTS9	100 fold relative to control
Ezzedine et al. 2011	INTS10	Below 3 fold relative to control
Ezzedine et al. 2011	INTS11	Above 3 but below 10 fold relative to control
Ezzedine et al. 2011	INTS12	3 fold relative to control
Chen et al 2012	INTS12	Moderate
Chen et al 2012	INTS12	Moderate
Chen et al 2012	INTS9	Above 30 but below 100 fold relative to

		control
Chen et al 2012	INTS9	Above 10 but below 30 fold relative to control
Chen et al 2012	INTS12	Above 1 but below 3 fold relative to control
Chen et al 2012	INTS12	Above 1 but below 3 fold relative to control
Chen et al 2013	INTS12	Moderate
Chen et al 2013	INTS12	Moderate
Chen et al 2013	INTS12	Between 5 to 7 fold relative to control
Chen et al 2013	INTS12	Between 1 to 3 fold relative to control
Chen et al 2013	INTS12	Between 3 to 5 fold relative to control
Chen et al 2013	INTS12	Between 3 to 5 fold relative to control
Chen et al 2013	INTS12	No effect
Baillat et al. 2005	INTS11	3 fold relative to control
Baillat et al. 2005	INTS11	4 fold relative to control
Baillat et al. 2005	INTS1	2 fold relative to control
Baillat et al. 2005	INTS1	4 fold relative to control

- 1 **Supplemental Methods**
- 2 **Lung function associated gene Integrator Complex subunit 12**
- 3 **regulates protein synthesis pathways**
- 4 Kheirallah et al.

## 5 **Cell Culture**

6 Human bronchial epithelial cells (HBEC) were purchased from Clonetics-Biowhittaker (MD, USA).  
7 Cells were cultured in HBEC basal medium (BEGM) from Lonza (Berkshire, UK; Product code CC-  
8 2540) prepared by addition of all the recommended supplements per manufacturer specifications  
9 excluding gentamicin. All laboratory experiments were performed using passage 3 cells. Prior to  
10 experiments cells were grown at 37°C with 5% CO<sub>2</sub> until ~95% confluent with BEGM media change  
11 every ~48h.

## 12 **RNAi**

13 Interferin (Polyplus Transfection) was used for gene knockdown optimizations. INTS12 silencing  
14 efficiency was tested using D-siRNAs A, B and C (OriGene, Table S3). Subsequently D-siRNAs A  
15 and C were tested at 0.1nM, 1nM and 10nM concentrations and a concentration of 1nM was chosen  
16 for optimal silencing efficiency. Two D-siRNAs were used in the experiments to account for off-  
17 target effects and thus to internally validate our observations. For main RNAseq and functional  
18 experiments the effects of INTS12 depletion were assessed 120h after initiation of interference. To  
19 ensure appropriate knockdown D-siRNA transfections were administered on two occasions at days  
20 zero and three of the experiment. To compare the acute and chronic transcriptomic responses to  
21 knockdown, RNAseq profiling was also performed 48h after the initiation of interference. In all  
22 experiments there were four experimental conditions: un-transfected cells, cells transfected with  
23 scrambled D-siRNA control, and cells transfected with D-siRNAs A and C. Each experimental  
24 condition was performed in three independent biological replicates.

## 25 **RNAseq**

26 Total RNA was extracted using a mammalian total RNA prep kit with on-column DNaseI digestion  
27 (Sigma-Aldrich). Sequencing samples were ensured to have RNA integrity number scores greater  
28 or equal to 8 (Agilent Technologies). The sequencing libraries were prepared with Illumina TruSeq  
29 RNA Sample Prep Kit v2. mRNA was poly-A selected by capturing total RNA samples with oligo-dT  
30 coated magnetic beads. The mRNA was then fragmented and randomly primed. cDNA was  
31 synthesised using random primers. Finally, a ready-for-sequencing library was prepared by end-  
32 repair, phosphorylation, A-tailing, adapter ligation and PCR amplification. Paired-end sequencing  
33 was performed on the HiSeq2000 platform (Illumina) using TruSeq v3 chemistry over 100 cycles  
34 yielding approx. 40 million reads per sample.

## 35 **qPCR**

36 Cultured cells were lysed and RNA was extracted using silica-membrane columns (Sigma-Aldrich).  
37 1µg of total RNA was converted to cDNA using the SuperScript synthesis system leveraging  
38 random hexamer priming (Invitrogen). Prior to reverse transcription, RNA was treated with DNaseI  
39 for a second time to ensure complete removal of any remaining traces of genomic DNA (gDNA).  
40 Each reverse transcriptase positive sample had equivalent reverse transcriptase negative control  
41 sample. For TaqMan assays (Applied Biosystems) the final volume of qPCR mix per single well was  
42 20µl consisting of 2µl of cDNA template, 6.4µl of DNase and RNase free water, 0.3µM of forward  
43 primer, 0.3µM of reverse primer, 0.1µM of probe, and 10µl of x2 TaqMan master mix (Applied  
44 Biosystems). For SYBR Green assays the final volume of qPCR mix per single well was 25µl  
45 consisting of 5µl of cDNA template, 6.4µl of DNase and RNase free water, 0.25µM of forward  
46 primer, 0.25µM of reverse primer, and 12.5µl of x2 Brilliant III Ultra-Fast SYBR Green master mix  
47 (Agilent). Reverse transcriptase positive samples were run in triplicate while reverse transcriptase  
48 negative samples were run in duplicates. Every qPCR ran had a water only control. qPCR oligo  
49 sequences are shown in the Table S4. Housekeeping GAPDH expression was run using pre-  
50 developed assay reagents (Life Technologies). QPCR-derived relative to GAPDH and control gene  
51 expression was analysed using  $\Delta\Delta C_t$  method [62]. QPCR technical validation of RNAseq findings  
52 was performed using at least three biological cDNA replicates derived from total RNA used in  
53 sequencing thus were upon the same donor cells. QPCR biological validation of target genes was  
54 performed upon different donor cells with at least three biological cDNA replicates.

## 55 **RNAseq and Pathway Data Analysis**

56 The quality of raw fastq files was assessed on fastqc. Tuxedo analysis pipeline was used for  
57 RNAseq analysis [63]: (1) TopHat read alignment was performed upon hg19 build, (2) Cufflinks  
58 transcriptome assembly was performed on individual sample basis and merged by Cuffmerge using  
59 reference-based assembly, (3) Cuffdiff differential gene expression was performed using  
60 Cuffmerge-predicted annotation. Loci with Benjamin-Hochberg corrected P value [60] below 0.05  
61 were considered significant. Transcriptomic comparisons were performed comparing scrambled D-  
62 siRNA to each anti-INTS12 D-siRNA and comparing un-transfected cells with scrambled D-siRNA  
63 transfected cells in order to account for off-target and mere transfection effects respectively.

64 In order to perform pathway analyses, fragments per kilobase per million reads (FPKM) expression  
65 values were obtained for each gene per individual RNAseq sample using Cuffnorm. Loci containing  
66 multiple amalgamated genes were separated into individual genes and had assigned the equivalent  
67 expression values, while genes occurring multiple times on the dataset had their expression values  
68 summated using in-house written python script. Scripts can be accessed on GitHub repository  
69 ([https://github.com/msxakk89/dataset\\_preperation\\_scripts](https://github.com/msxakk89/dataset_preperation_scripts)). Gene set enrichment analysis using  
70 4722 curated gene sets including 1320 canonical pathway definitions from the Molecular  
71 Signatures Database [35] was used, comparing scrambled D-siRNA to each anti-INTS12 D-siRNA  
72 and comparing un-transfected cells with scrambled D-siRNA transfected cells. Pathways with  
73 Benjamin-Hochberg corrected P value below 0.05 were considered significant. Pathways  
74 reproducibly dysregulated by the two different D-siRNA treatments were considered further. Top  
75 candidate pathways with the highest enrichment score in both D-siRNAs were chosen for further  
76 functional analysis. Results of the pathway analysis were displayed in a Cleveland's plot using  
77 ggplot2 R package while pathway heatmaps were drawn using heatplus R package. Boxplots were  
78 drawn using build-in R function. Pearson's correlations of gene expression were calculated using  
79 hmisc R package and drawn using ggplot2.

80 Comparison of acute and chronic transcriptomic responses to INTS12 knockdown aimed at  
81 identifying core subset genes significantly differentially expressed in 48h and 120h time points  
82 respectively. The rational of the analysis was similar to pathway analysis, i.e. genes were  
83 shortlisted if were reproducibly dysregulated in both anti-INTS12 D-siRNAs but not in scrambled D-  
84 siRNA. Genes that were dysregulated in both anti-INTS12 D-siRNAs in a given direction while in  
85 the opposite direction in the scrambled D-siRNA sample were also included.

86 Core subset of genes was identified by determining the common genes between the 48h and 120h  
87 significant gene lists. Enrichment of lung biology relevant gene set was performed via Fisher's  
88 exact over-representation analysis using the background of protein coding genes. Correlation of  
89 INTS12 with INTScom was calculated by averaged Pearson's correlation over all the complex  
90 members.

91

92

93

94 **Protein synthesis by <sup>35</sup>S-Methionine incorporation assay**

95 Rates of protein synthesis were measured using EasyTag <sup>35</sup>S protein labelling for 10 minutes in  
96 labelling medium, followed by lysis of cells in passive lysis buffer (Promega) and TCA precipitation  
97 on filter paper as described previously for NIH3T3 cells [64]. Three biological replicates with four  
98 technical replicates each were performed. In parallel, the same samples were assayed for total  
99 protein using 200µl Coomassie Protein Assay Reagent (Thermo) with 10µl of lysate in microtitre  
100 plates and a Synergy HT plate reader (Biotek) at 595 nm. Background for lysis buffer alone was  
101 subtracted. For each replicate, the radioactive incorporation was divided by the protein assay  
102 measurements thus yielding a measure of incorporation per amount of total protein. Statistical  
103 significance of difference in protein synthesis in INTS12 depleted cells was determined by one-way  
104 ANOVA analysis of variance followed by Fisher's Least Significant Difference test.

105 **Assessment of proliferative capacity by cell counts**

106 Proliferative capacity was assessed by comparing total cell counts at the beginning and at end of  
107 the knockdown, i.e. at the beginning of experiment cells were seeded at the same density in all  
108 the conditions. At the end HBECs were washed with PBS, treated with trypsin/EDTA at 37°C for  
109 10min to allow all the cells to detach and were re-suspended in 1ml of culture media. Samples  
110 were coded and mixed to perform counting without knowledge of the condition and conditions  
111 were decoded later. Cell counts were performed on haemocytometer in technical triplicate per each  
112 condition, averaged and total cell count estimates derived accordingly. Experiment was performed  
113 in four biological replicates.

114

115

116

117

118

119

120

## 121 **ChIPseq**

122 HBECs from two different donors were fixed with formaldehyde solution for 15 min. Formaldehyde  
123 solution contained 11% formaldehyde (Sigma), 0.1M sodium chloride (Sigma), 1mM EDTA  
124 (Sigma), 50mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Appllichem). Fixation was  
125 quenched with 0.125 M glycine (Sigma). Chromatin was isolated by the addition of lysis buffer  
126 (Active Motif), followed by disruption with a Dounce homogenizer (Active Motif) to allow for  
127 efficient chromatin preparation. Lysates were sonicated and the DNA sheared to an average length  
128 of 300-500bp. Genomic DNA for each replicate sample was prepared by treating aliquots of  
129 chromatin with RNase, proteinase K and heat for de-crosslinking, followed by ethanol precipitation  
130 (Active Motif). Pellets were re-suspended and the resulting DNA was quantified on a NanoDrop  
131 spectrophotometer. Extrapolation to the original chromatin volume allowed quantitation of the  
132 total chromatin yield. 30µg chromatin of each sample was precleared with protein A agarose beads  
133 (Invitrogen). Unprecipitated genomic DNA (i.e. input control) was prepared from a pool of equal  
134 aliquots of the two donor samples. Genomic DNA regions of interest were isolated using 4µg of  
135 antibody against INTS12 (Sigma cat. num. HPA03577) following manufacturer's specifications  
136 (Active Motif). Complexes were washed, eluted from the beads with SDS buffer, and subjected to  
137 RNase and proteinase K treatment. Crosslinks were reversed by incubation overnight at 65°C, and  
138 ChIP DNA was purified by phenol-chloroform extraction and ethanol precipitation. Initially a pilot  
139 experiment was conducted where DNA libraries obtained from single donor were sequenced on  
140 NextSeq 500 sequencing machine (Illumina) yielding ~8 million single-ended 75bp reads in order  
141 to assess the success of ChIPseq. For the definite experiment, sequencing libraries (Illumina) were  
142 prepared from the both ChIP and input DNAs and the resulting libraries were sequenced yielding  
143 ~40 million reads per two ChIP samples from each donor cells and one input control of both  
144 donors.

## 145 **ChIP-PCR**

146 INTS12 peak regions used for qPCR validation were prioritized based on ChIPseq signals observed  
147 on the genome browser. Three positive regions and one negative region were chosen for ChIP-PCR  
148 validation. PCR primers were designed to span these regions (Table S5). qPCR reactions were  
149 carried out in triplicate upon 12.5ng of gDNA from each donor and input control using SYBR Green  
150 assay (Bio-Rad). Ct values were converted into the number of binding events detected per 1000  
151 cells according to the manufacturers of ChIP-PCR kit specifications (Active Motif).

## 152 **ChIPseq Data Analysis**

153 Reads were BWA aligned [65] to hg19 using default settings. Artefactual read duplicates were  
154 removed using samtool prior to further analyses. MACS INTS12 peak calling was run on each  
155 donor separately comparing ChIPseq samples to input control [66]. Calling was performed with a  
156 multiple comparisons corrected P value of less than 0.05 considered as significant. Generated  
157 fragment pileup signal was normalized to library size. Fragment pileup was converted to wig files  
158 based on fold enrichment above input background for each donor. To compare peak metrics  
159 between two donor samples, overlapping intervals were grouped into active regions, which were  
160 defined by the start coordinate of the most upstream interval and the end coordinate of the most  
161 downstream interval. In locations where only one sample had an interval, this interval defined the  
162 active region. ChIP signal at these active regions was compared between the two donor samples  
163 and correlation drawn and calculated by ggplot2 and rcmdr R packages respectively. Intervals  
164 were annotated, percentage of total INTS12 binding sites falling on the fixed annotated genomic  
165 features and enrichment over meta-gene body determined using CEAS package [67]. The  
166 proportion of binding proximal to TSS was calculated by dividing the number of significant peaks  
167 close the TSS ( $TSS \pm 1000bp$ ) by the number of significant peaks falling within the broader region  
168 surrounding the TSS ( $TSS \pm 3000$ ). Enrichment over various gene classes, expressed/not  
169 expressed, or differentially expressed genes was drawn using ngs.plot [68]. Gene classes were  
170 retrieved using Ensembl's BioMart tool. HOMER and MEME were used for *de novo* identification of  
171 enriched DNA motif at INTS12 binding sites [51, 52]. TomTom was used to compare *de novo*  
172 identified motif to a set of currently known motifs [53]. BETA was used to predict INTS12  
173 regulatory function [49].

## 174 **ENCODE data retrieval and analysis**

175 Airway epithelial cells specific epigenetic and CTCF ChIPseq datasets were obtained from ENCODE  
176 data repository (ENCBS417ENC; [www.encodeproject.org](http://www.encodeproject.org)) and analysed as INTS12 ChIPseq  
177 datasets with the only difference that broad region calling was used for the epigenetic marks.  
178 Percent of overlap between INTS12 intervals and ENCODE intervals and its statistical significance  
179 was determined using regioneR R package with random permutation test. Correlation of ChIPseq  
180 signals and conservation of binding analyses were performed using cistrome [69].

181

182 **Immunofluorescence**

183 Cells were grown on 8-chamber glass slides seeding 8000 cells onto each chamber and were left  
184 un-treated or were transfected with anti-INTS12 and scrambled D-siRNAs as described previously.  
185 Cells were fixed using 4% formaldehyde and blocked/permeabilized with PBS, 10% goat serum,  
186 1% BSA, and 0.15% Triton-X. Cells were incubated with antibody against INTS12 (Sigma cat.  
187 num. HPA03577) at 4°C overnight and rhodamine-TRITC labelled secondary for 1 hour at room  
188 temperature. Controls were incubated with primary isotype control (Abcam) antibody followed by  
189 secondary antibody. Cells were visualized epifluorescently and exposures were kept constant  
190 across the conditions to avoid artefactual differences in the observed fluorescence intensity.

191

192